To investigate BCG tolerability and response with respect to timing of BCG administration following TUR in patients with non-muscle invasive bladder cancer (NMIBC).
A review of NMIBC patients at our institution managed with at least ‘adequate BCG’ (defined by the US FDA as at least 5/6 induction instillations with 2 additional instillations comprising either maintenance or repeat induction) at our institution from 2000-2018 was performed.